MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer

被引：0
|
作者：
Michael J. G. Milevskiy
Udai Gujral
Carolina Del Lama Marques
Andrew Stone
Korinne Northwood
Lez J. Burke
Julia M. W. Gee
Kenneth Nephew
Susan Clark
Melissa A. Brown
机构：
[1] University of Queensland,School of Chemistry and Molecular Biosciences
[2] Garvan Institute of Medical Research,Division of Genomics and Epigenetics, Epigenetics Research Laboratory
[3] The University of Queensland,UQ Centre for Clinical Research
[4] Cardiff University,School of Pharmacy and Pharmaceutical Sciences
[5] Indiana University,School of Medicine
[6] The Walter and Eliza Hall Institute of Medical Research,ACRF Stem Cells and Cancer
来源：
British Journal of Cancer | 2019年 / 120卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：621 / 632
页数：11
相关论文
共 50 条
  • [31] PICTILISIB PLUS ANASTROZOLE REDUCES PROLIFERATION IN ER+ BREAST CANCER
    不详
    CANCER DISCOVERY, 2016, 6 (05) : 471 - 471
  • [32] TMEM doorway score as a predictive biomarker for therapy selection in ER+/HER2-breast cancer
    Parmar, Priyanka
    Miller, Andrew
    Karadal-Ferrena, Burcu
    Shukla, Suryansh
    Huang, Cien
    Ginsberg, Mindy
    Rosenbaum, Chedva
    Felder, Malka
    Zhang, Chenxin
    Condeelis, John S.
    Xue, Xiaonan
    Rohan, Thomas E.
    Sparano, Joseph A.
    Anampa, Jesus D.
    Entenberg, David
    Oktay, Maja H.
    CANCER RESEARCH, 2024, 84 (22)
  • [33] ANDROGEN RECEPTOR FUNCTIONS AS A TUMOR SUPPRESSOR IN ER+ BREAST CANCER
    不详
    CANCER DISCOVERY, 2021, 11 (03) : 530 - 530
  • [34] CCNA2 Is a Prognostic Biomarker for ER plus Breast Cancer and Tamoxifen Resistance
    Gao, Tian
    Han, Yong
    Yu, Ling
    Ao, Sheng
    Li, Ziyu
    Ji, Jiafu
    PLOS ONE, 2014, 9 (03):
  • [35] GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome
    West, Diana C.
    Pan, Deng
    Tonsing-Carter, Eva Y.
    Hernandez, Kyle M.
    Pierce, Charles F.
    Styke, Sarah C.
    Bowie, Kathleen R.
    Garcia, Tzintzuni I.
    Kocherginsky, Masha
    Conzen, Suzanne D.
    MOLECULAR CANCER RESEARCH, 2016, 14 (08) : 707 - 719
  • [36] ER−/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection
    Wei Ying
    Sumeng Wang
    Junfeng Shi
    Yujie Sun
    Medical Oncology, 2012, 29 : 495 - 502
  • [37] The greater impact of menopause on ER– than ER+ breast cancer incidence: a possible explanation (United States)
    Robert E. Tarone
    Kenneth C. Chu
    Cancer Causes & Control, 2002, 13 : 7 - 14
  • [38] Bioinformatics Identification of TUBB as Potential Prognostic Biomarker for Worse Prognosis in ERα-Positive and Better Prognosis in ERα-Negative Breast Cancer
    Alhammad, Rashed
    DIAGNOSTICS, 2022, 12 (09)
  • [39] Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer
    Liu, Xiao-ran
    Zhang, Ru-yan
    Gong, Hao
    Rugo, Hope S.
    Chen, Ling-bo
    Fu, Yuan
    Che, Jian-wei
    Tie, Jian
    Shao, Bin
    Wan, Feng-ling
    Kong, Wei-yao
    Song, Guo-hong
    Jiang, Han-fang
    Xu, Guo-bing
    Li, Hui-ping
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [40] Palbociclib Ups PFS in HER2-/ER+ Breast Cancer
    不详
    CANCER DISCOVERY, 2014, 4 (06) : 624 - 625
12345